# US 2025/0082782 A1 · Transgene cassettes designed to express the human codon-optimized gene fmr1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082782 A1
- Document ID: US20250082782A1
- Status: Published application
- Kind: A1
- Application number: 18/729,389
- Filed: 2023-01-27
- Published: 2025-03-13
- Earliest claimed: 2022-01-28
- Assignees: Board of Regents, The University of Texas System; The Governing Council of the University of Toronto
- Applicants: The Board of Regents of the University of Texas System; The Governing Council of the University of Toronto
- Inventors: Steven J. GRAY; David R. HAMPSON; Hye Ri KANG; Hayes Ga-Hei WONG; Alexander W.M. HOOPER
- Web page: https://patentgrep.com/patent/US20250082782A1

## CPC

- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 15/86: Viral vectors
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14145: Special targeting system for viral vectors
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C12N 2820/007: tissue or cell-specific
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This technology relates to polynucleotides comprising optimized FMR1 open reading frame (ORF) sequences, viral vectors comprising the same, and methods of using the same for delivery of the ORF to a cell or a subject and to treat disorders associated with aberrant expression of FMR1, such as Fragile X syndrome (“FXS”).

## Claims

### Claim 1

A recombinant adeno-associated virus (rAAV) vector comprising in 5′ to 3′ direction:
a) a first AAV ITR sequence;
b) a promoter sequence;
c) a transgene nucleic acid molecule, wherein the transgene nucleic acid molecule comprises a sequence that is at least 90% identical to the sequence set forth in SEQ ID NO: 4;
d) a polyA sequence; and
e) a second AAV ITR sequence.

### Claim 2 (depends on 1)

The rAAV vector of claim 1, wherein the transgene nucleic acid molecule comprises the nucleic acid sequence set forth in SEQ ID NO:4.

### Claim 3 (depends on 1)

The rAAV vector of claim 1, wherein the vector comprises SEQ ID NO: 1, 7, or 9.

### Claim 4

The rAAV vector of any one of the preceding claims, wherein the transgene nucleic acid sequence encoding for an FMRP polypeptide exhibits at least 5%, at least 10%, at least 20%, at least 30%, at least 50%, at least 75%, at least 100%, at least 200%, at least 300%, at least 500%, or at least 1000% increased expression in a human subject relative to a mutated FMR1 nucleic acid sequence.

### Claim 5

The rAAV vector of any one of the preceding claims, wherein the first AAV ITR sequence comprises the nucleic acid sequence set forth in SEQ ID NO:2.

### Claim 6

The rAAV vector of any one of the preceding claims, wherein the second AAV ITR sequence comprises the nucleic acid sequence set forth in SEQ ID NO:6.

### Claim 7

The rAAV vector of any one of the preceding claims, wherein the promoter sequence comprises a Rous sarcoma virus (RSV) LTR promoter (optionally with an RSV enhancer), a cytomegalovirus (CMV) promoter, an SV40 promoter, a dihydrofolate reductase promoter, a beta-actin promoter, a phosphoglycerol kinase (PGK) promoter, a U6 promoter, a JetI promoter, an H1 promoter, a CAG promoter, a hybrid chicken beta-actin (CBA) promoter, an MeCP2 promoter, an EF1 promoter, a ubiquitous chicken β-actin hybrid (CBh) promoter, a U1a promoter, a U1b promoter, an MeCP2 promoter, an MeP418 promoter, an MeP426 promoter, a minimal MeCP2 promoter, a VMD2 promoter, an mRho promoter, EFla promoter, Ubc promoter, human β-actin promoter, a synapsin (hSyn) promoter sequence, TRE promoter, Ac5 promoter, Polyhedrin promoter, CaMKIIa promoter, Gal1 promoter, TEF1 promoter, GDS promoter, ADH1 promoter, Ubi promoter, or α-1-antitrypsin (hAAT) promoter.

### Claim 8

The rAAV vector of any one of the preceding claims, wherein the promoter sequence comprises the nucleic acid sequence set forth in SEQ ID NO:3, 8, 10, 35, or 36.

### Claim 9

The rAAV vector of any one of the preceding claims, wherein the polyA sequence comprises the nucleic acid sequence set forth in SEQ ID NO:5.

### Claim 10

An rAAV vector of any one of the preceding claims, comprising, in the 5′ to 3′ direction:
a) a first AAV ITR sequence comprising the nucleic acid sequence set forth in SEQ ID NO:2;
b) a promoter sequence comprising the nucleic acid sequence set forth in SEQ ID NO:3, 7, 10, 35, or 36;
c) a transgene nucleic acid molecule, wherein the transgene nucleic acid molecule comprises a nucleic acid sequence encoding for an FMRP polypeptide, wherein the nucleic acid sequence encoding for an FMRP polypeptide comprises the nucleic acid sequence set forth in SEQ ID NO:4;
d) a polyA sequence comprising the nucleic acid sequence set forth in SEQ ID NO:5; and
e) a second AAV ITR sequence comprising the nucleic acid sequence set forth in SEQ ID NO:6.

### Claim 11

An rAAV viral vector comprising:
(i) an AAV capsid protein; and
(ii) an rAAV vector of any one of the preceding claims.

### Claim 12 (depends on 11)

The rAAV viral vector of claim 11, wherein the AAV capsid protein is an AAV9 capsid protein.

### Claim 13 (depends on 11, 12)

A pharmaceutical composition comprising:
a) the rAAV viral vector of claim 11 or 12; and at least one pharmaceutically acceptable excipient and/or additive.

### Claim 14 (depends on 11, 12, 13)

A method for treating a subject having a disease and/or disorder involving an FMR1 gene, the method comprising administering to the subject at least one therapeutically effective amount of the rAAV viral vector of claim 11 or 12 or the pharmaceutical composition of claim 13.

### Claim 15 (depends on 14)

The method of claim 14, wherein the disease and/or disorder involving an FMR1 gene is Fragile X syndrome (FXS), a FMR1 premutation with or without Fragile X-associated tremor/ataxia, or X-related Premature Ovarian Insufficiency.

### Claim 16 (depends on 14, 15)

The method of claim 14 or claim 15, wherein the rAAV viral vector or the pharmaceutical composition is administered to the subject at a dose ranging from about 1011 to about 1018 viral vector particles.

### Claim 17 (depends on 16)

The method of claim 16, wherein the rAAV viral vector or the pharmaceutical composition is administered to the subject at a dose ranging from about 1013 to about 1016 viral vector particles.

### Claim 18 (depends on 14, 15, 16, 17)

The method of any one of claim 14-17, wherein the rAAV viral vector or pharmaceutical composition is administered into the cerebrospinal fluid.

### Claim 19 (depends on 14, 15, 16, 17)

The method of any one of claim 14-17, wherein the rAAV viral vector or pharmaceutical composition is administered intracisternal-magna, intrathecally, or intra-cerebroventricular.

### Claim 20 (depends on 11, 12, 13)

The rAAV viral vector of claim 11 or 12 or the pharmaceutical composition of claim 13 for use in treating a disease and/or disorder involving an FMR1 gene in a subject in need thereof.

### Claim 21 (depends on 20)

The use of claim 20, wherein the disease and/or disorder involving an FMR1 gene is FXS, a FMR1 premutation with or without Fragile X-associated tremor/ataxia, or X-related Premature Ovarian Insufficiency.

### Claim 22 (depends on 21, 22)

The use of claim 21 or claim 22, wherein the rAAV viral vector or the pharmaceutical composition is for administration to the subject at a dose ranging from about 1011 to about 1018 viral vector particles.

### Claim 23 (depends on 20, 21, 22)

The use of any of claims 20-22, wherein the rAAV viral vector or the pharmaceutical composition is for administration to the subject at a dose ranging from about 1013 to about 1016 viral vector particles.

### Claim 24 (depends on 20, 21, 22, 23)

The use of any one of claims 20-23, wherein the rAAV viral vector or pharmaceutical composition is for administration into the cerebrospinal fluid.

### Claim 25 (depends on 20, 21, 22, 23)

The use of any one of claims 20-23, wherein the rAAV viral vector or pharmaceutical composition is for administration intracisterna-magna, intrathecally, or intra-cerebroventricular.
